There is evidence that intraneural accumulation of the processed products of APP, together with phosphorylated tau, affects synaptic function leading to the cognitive defects associated with Alzheimer’s disease [for reviews (Bayer and Wirths, 2010; Spires-Jones and Hyman, 2014)]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.